Optos Reports Over 150 MonacoPro Sales as Practices Prioritize Diagnostic Innovation

 

Dunfermline, UK – 3 June 2025 – Optos PLC, a global leader in retinal imaging technology, today announced the milestone achievement of the 150th worldwide sale of its MonacoPro device—just over 100 days after product launch. This rapid adoption underscores the strong demand for Optos’ advanced retinal imaging solutions and further establishes Optos as the global leader in the field.

“We are extremely proud to have reached this significant milestone in such a short period of time,” said Optos Deputy CEO Quinn Lyzun. “This accomplishment reflects the confidence and trust that eye care professionals worldwide place in our technology and our commitment to improving patient outcomes.”

Key Product Features:

• • MonacoPro OCT Image Quality for Demanding Practices
    New MonacoPro OCT image quality provides highly detailed and precise retinal images that meet the needs of even the most demanding eyecare practices. With MonacoPro, practitioners can visualize and assess retinal layer integrity  with greater accuracy, supporting diagnosis and treatment planning. When combined with the integrated 200° single-shot optomap imaging, MonacoPro increases the identification of macular pathology when compared with fundus imaging alone by 29.4%.¹ 
  • AreaAssist: Streamlined Efficiency for Enhanced Workflow
    MonacoPro also marks the introduction of the new AreaAssist tool, designed to improve the efficiency of retinal imaging workflows. AreaAssist enables users to automatically measure continuous areas of matching color and adjust the sensitivity of the selected area with a simple “click and drag” of the mouse. By automating and simplifying these processes, AreaAssist removes the need for time-consuming manual tasks, allowing practitioners to focus on patient care and clinical decision-making. 
  • One of the Largest Reference Databases in Retinal Imaging
    The Optos Reference Database in the US market, on the MonacoPro now includes 879 eyes and stratifies based on different optic disc sizes in addition to age. Research has demonstrated that normalizing reference data by ONH size is a more effective approach than other criteria for identifying relevant population data, leading to greater diagnostic precision.² 

Optos continues to innovate in retinal imaging with a focus on empowering eyecare professionals to diagnose and manage ocular conditions more effectively. Alongside the Optos product suite, MonacoPro reflects the company’s commitment to delivering high-performance tools that streamline workflows, support clinical precision, and elevate patient care.

For more information about MonacoPro and industry-leading retinal imaging technology by Optos, please visit www.optos.com.

References & Supporting Research: 

1. Aiello et al.: INTEGRATING MACULAR OPTICAL COHERENCE TOMOGRAPHY WITH ULTRAWIDE-FIELD IMAGING IN A DIABETIC RETINOPATHY TELEMEDICINE PROGRAM USING A SINGLE DEVICE. Retina 2023 Nov 1;43(11):1928-1935.
2. Salazar et al.: Optical Coherence Tomography Measurement Correlations with Age and Optic Disc Size. Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4848
• Chaglasian et al.: Accuracy of Glaucoma Detection with a Novel Imaging Device: Combined UWF-SLO and SD-OCT. Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4841
• Sinai et al.: Structure and Function Relationship in Glaucoma with a Novel Multi-Modal Imaging Device Combining UWF-SLO and SD-OCT. Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2541

About Optos
For more than 30 years, Optos has been the exclusive provider of 200-degree single-shot ultra-widefield retinal imaging systems to eye care professionals worldwide. With over 27,000 devices in use and supported by more than 3,000 clinical papers,

Optos has also developed integrated ultra-widefield retinal imaging with optomap-guided Optical Coherence Tomography (OCT). Optos devices facilitate the early detection, management, and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. Optos continues to lead the way in retinal imaging technology, setting the standard for excellence and innovation in eye care

Media Contact:
Cassy Dump
Shine Communications for Optos
Cassy@heyshine.com
(619) 971-1887

Organization Contact:
Sharon Shepard
Senior Director, Marketing, North America
sshepard@optos.com